Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 1 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 28 % of short-term debt in 2021; threshold 65 %.
-
Late annual account NBB
Fiscal year 2021 was filed 422 days after the legal deadline.
-
Annual account missing NBB
Fiscal year 2022 was expected before 31 July 2023 and has not been filed.
-
Busy address KBO
19 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2021
ReGenesys EU from Leuven, company number BE0544577301, closed financial year 2021 with a result of € -10,187 after tax. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 26, 2023.
€ -20,027
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -10,187
Profit after tax over the fiscal year.
€ 7,609
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -81,527.
Debts at end 2021
None
No bank loans on the last day of the fiscal year.
€ 636
Supplier invoices still open on the last day of the fiscal year.
Ask about ReGenesys EU the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to ReGenesys EU?
What happened at ReGenesys EU in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Dan Camardo stepped down as director. NBB
- New annual accounts for financial year 2021: loss of € 10,187. filed late Source: NBB ↗
- Dan Camardo became a director. NBB
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Leuven. KBO
In short
Pays suppliers within 26 days on average.
Management
The shares are held by ReGenesys BV (99.2%) and Advanced Biotherapeutics Inc. (0.8%).
Directors
According to the 2021 annual accounts
Dan Camardo
Director
since 2022 · until 2028
Shareholders
99.2%
Advanced Biotherapeutics Inc.
0.8%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 1
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 19 companies are registered at this address.
All companies at this address →reMYND
€ -217,249 gross margin · 2025
DName-iT
€ -71,430 gross margin · 2025
miDiagnostics
€ 24,934 revenue · 2025
Pledge Therapeutics
€ -644,682 gross margin · 2025
PALEO
€ 1.5 million gross margin · 2025
+14 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- ReGenesys(oprichter) 99.2%
- Advanced Biotherapeutics, Inc.(oprichter) 0.8%
Details
- Company number
- 0544.577.301
- VAT number
- BE 0544.577.301
- Registered office
- Gaston Geenslaan 1, 3001 Leuven
- Names & denominations
- ReGenesys EU
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 30 December 2013
- Peppol
- Not registered